Quick Answer
ENANTA PHARMACEUTICALS INC reported Total Revenue of $65.32 million for fiscal year 2025.
ENANTA PHARMACEUTICALS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $65.32M -3.4% |
$67.64M -14.6% |
$79.20M -8.1% |
$86.16M -11.2% |
$97.07M -20.7% |
$122.47M -40.3% |
| Revenue (ASC 606) | $65.32M -3.4% |
$67.64M -14.6% |
$79.20M -8.1% |
$86.16M -11.2% |
$97.07M -20.7% |
$122.47M -40.3% |
| Net Income | -$81.89M +29.4% |
-$116.05M +13.3% |
-$133.82M -9.9% |
-$121.75M -54.1% |
-$79.00M -118.4% |
-$36.17M -178.0% |
| Diluted EPS | -$3.84 +29.9% |
-$5.48 +14.1% |
-$6.38 -8.0% |
-$5.91 -50.8% |
-$3.92 -116.6% |
-$1.81 -181.9% |
| Total Assets | $280.73M -25.5% |
$376.65M -18.5% |
$462.27M +23.1% |
$375.41M -14.4% |
$438.79M -9.7% |
$486.13M -0.8% |
| Cash and Equivalents | $32.30M -13.3% |
$37.23M -56.4% |
$85.39M +94.1% |
$43.99M -23.1% |
$57.21M -34.3% |
$87.13M +70.1% |
| Stockholders Equity | $64.72M -49.8% |
$128.81M -40.6% |
$216.74M -32.6% |
$321.33M -19.6% |
$399.43M -12.3% |
$455.58M -1.5% |
| R&D Expense | $106.74M -18.8% |
$131.48M -19.6% |
$163.52M -0.6% |
$164.52M -5.5% |
$174.11M +27.3% |
$136.76M -3.8% |
| Operating Income | -$85.35M +29.9% |
-$121.69M +11.3% |
-$137.21M -10.8% |
-$123.84M -13.0% |
-$109.57M -163.1% |
-$41.64M -213.3% |
| Shares Outstanding | 21.39M +0.9% |
21.19M +0.6% |
21.06M +1.3% |
20.79M +2.7% |
20.24M +0.8% |
20.08M +1.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $18.61M | +9.8% | +1.6% |
| Revenue (ASC 606) | December 31, 2025 | $18.61M | +9.8% | +1.6% |
| Net Income | December 31, 2025 | -$11.94M | +46.4% | +34.6% |
| Diluted EPS | December 31, 2025 | -$0.42 | +60.0% | +50.6% |
| Total Assets | December 31, 2025 | $329.50M | -5.5% | +17.4% |
| Cash and Equivalents | December 31, 2025 | $37.44M | -55.6% | +15.9% |
| Stockholders Equity | December 31, 2025 | $126.59M | +13.2% | +95.6% |
| R&D Expense | December 31, 2025 | $20.86M | -24.6% | -23.3% |
| Operating Income | December 31, 2025 | -$11.25M | +52.2% | +40.4% |
| Shares Outstanding | December 31, 2025 | 29.02M | +36.0% | +35.7% |
- ENANTA PHARMACEUTICALS INC reported Total Revenue of $65.32 million for fiscal year 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -3.4% in Total Revenue compared to the prior fiscal year.
- ENANTA PHARMACEUTICALS INC reported Revenue (ASC 606) of $65.32 million for fiscal year 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -3.4% in Revenue (ASC 606) compared to the prior fiscal year.
- ENANTA PHARMACEUTICALS INC reported Net Income of -$81.89 million for fiscal year 2025.
- ENANTA PHARMACEUTICALS INC showed an increase of +29.4% in Net Income compared to the prior fiscal year.
- ENANTA PHARMACEUTICALS INC reported Diluted EPS of $3.84 per share (loss) for fiscal year 2025.
- ENANTA PHARMACEUTICALS INC showed an increase of +29.9% in Diluted EPS compared to the prior fiscal year.
- ENANTA PHARMACEUTICALS INC reported Total Assets of $280.73 million for fiscal year 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -25.5% in Total Assets compared to the prior fiscal year.
- ENANTA PHARMACEUTICALS INC reported Cash and Equivalents of $32.30 million for fiscal year 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -13.3% in Cash and Equivalents compared to the prior fiscal year.
- ENANTA PHARMACEUTICALS INC reported Stockholders Equity of $64.72 million for fiscal year 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -49.8% in Stockholders Equity compared to the prior fiscal year.
- ENANTA PHARMACEUTICALS INC reported R&D Expense of $106.74 million for fiscal year 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -18.8% in R&D Expense compared to the prior fiscal year.
- ENANTA PHARMACEUTICALS INC reported Operating Income of -$85.35 million for fiscal year 2025.
- ENANTA PHARMACEUTICALS INC showed an increase of +29.9% in Operating Income compared to the prior fiscal year.
- ENANTA PHARMACEUTICALS INC reported Shares Outstanding of 21.39 million shares for fiscal year 2025.
- ENANTA PHARMACEUTICALS INC showed an increase of +0.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: